Innovent’s Phase III trial of type 2 diabetes treatment meets endpoints
Participants in the trial were randomised into a 1: 1: 1 ratio to receive either 4mg or 6mg doses of mazdutide or a placebo.
22 July 2024
22 July 2024
Participants in the trial were randomised into a 1: 1: 1 ratio to receive either 4mg or 6mg doses of mazdutide or a placebo.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
Give your business an edge with our leading industry insights.